Department of Pharmaceuticals

We provide a variety of services to patients of the NCCHD, including a clinical pharmacy service, medication dispensing systems, information on medicines, and aseptic preparation services. We are also involved in a range of clinical trials. The main aim of our department is to provide patients with medicines that are safe and appropriate. We also engage in the development of pharmaceutical therapy for children in Japan.

Our team includes 30 pharmacists and four pharmacy residents, who all contribute to providing patients with the best possible care.

We have introduced several dispensing systems across the NCCHD to quickly and safely provide patients with correct prescription medications 24 hours a day.

Hospital preparation

All sterile drugs and medications are prepared at the NCCHD using aseptic techniques, and include products such as cytotoxic chemotherapy and total parenteral nutrition (intravenous feeding). Furthermore, to meet the
high demand for specific drugs currently unavailable to the public, we also prepare various specialized formulations according to patient needs.

Drugs are administrated by individual departments to ensure patients are provided with safe and appropriate medication. We also provide guidance about drug treatment.

Compliance with all rules and regulations regarding drug management is a key priority of the department. Narcotic drugs, psychotropic drugs, lethal drugs, powerful drugs, anti-cancer drugs, blood products and other high-risk drugs are all managed according to procedures established to guarantee proper usage.

We support patients, medical doctors, nurses and other medical staff with advice on prescribing medicine for patients in accordance with information provided by the drug manufacturer and the Ministry of Health, Labour and Welfare, Japan. Information on in-hospital adverse reactions to drugs is collected and reported to the Ministry.

We are involved in pharmaceutical education and train pediatric and perinatal pharmacists.

We actively participate in shaping public policy in order to promote the development of both current and new drug therapies for children and pregnant women.